News

Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis
Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in the Czech Republic for the treatment of active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis. Its efficacy compared to adalimumab in PsA was evaluated in the head-to-head SPIRIT-H2H study. A post-hoc analysis of this study focusing on a subpopulation of patients with PsA and concurrent moderate to severe plaque psoriasis was presented at the Congress of the European Academy of Dermatology and Venereology (EADV) in October 2019 in…

How to Improve Diabetic Adherence?

Should patients with primary immunodeficiencies fear COVID-19 more than the general population?

Safety and Efficacy of Negative Pressure Therapy in Acute Infected Wounds

Monotherapy with Bimatoprost in Patients with Glaucoma and Ocular Hypertension

Effectiveness of Arginine in Tooth Cleaning Proven (Not Only) by Quantitative Light-Induced Fluorescence

Concise and Practical Recommendations for Optimal Care of Dental Prostheses

Care for Dental Prostheses: What Did Clinical Study Results Reveal?

New Era in Migraine Therapy

Most Common Dermatoses Around the Stoma
Conferences
News from the world of medicine
All conferences
Popular this week
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Good, Bad, or Ugly? What's the Deal with Eggs?
- Modern approaches enhancing the efficiency of antibiotic therapy in hospital practice
- Patient blood management – past, present and future